ARS Pharmaceuticals Stock Price Up 6 percent Heres Why
SPRY Stock | 14.29 1.27 9.75% |
Slightly above 58% of all Silverback Therapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Silverback Therapeutics suggests that some traders are interested. Silverback Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Silverback Therapeutics' earnings reports, geopolitical events, and overall market trends.
Silverback |
ARS Pharmaceuticals, Inc. shares rose 6 percent on Thursday . The stock traded as high as 15.25 and last traded at 14.92. Approximately 353,461 shares traded hands during mid-day trading, a decline of 56 percent from the average daily volume of 801,062 shares. The stock had previously closed at 14.08. Wall Street
Read at thelincolnianonline.com
Silverback Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Silverback Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Silverback Therapeutics Fundamental Analysis
We analyze Silverback Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Silverback Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Silverback Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Silverback Therapeutics is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Silverback Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Silverback Therapeutics stock to make a market-neutral strategy. Peer analysis of Silverback Therapeutics could also be used in its relative valuation, which is a method of valuing Silverback Therapeutics by comparing valuation metrics with similar companies.
Peers
Silverback Therapeutics Related Equities
ZURA | Zura Bio | 6.82 | ||||
CUE | Cue Biopharma | 6.62 | ||||
ANNX | Annexon | 5.21 | ||||
INAB | In8bio | 4.00 | ||||
DRMA | Dermata Therapeutics | 2.50 | ||||
TCRX | Tscan Therapeutics | 0.39 | ||||
IMMX | Immix Biopharma | 1.52 | ||||
WVE | Wave Life | 4.06 | ||||
PALI | Palisade Bio | 4.90 | ||||
ALLR | Allarity Therapeutics | 5.08 | ||||
HEPA | Hepion Pharmaceuticals | 5.26 | ||||
CGTX | Cognition Therapeutics | 6.49 | ||||
WINT | Windtree Therapeutics | 7.14 |
Additional Tools for Silverback Stock Analysis
When running Silverback Therapeutics' price analysis, check to measure Silverback Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Silverback Therapeutics is operating at the current time. Most of Silverback Therapeutics' value examination focuses on studying past and present price action to predict the probability of Silverback Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Silverback Therapeutics' price. Additionally, you may evaluate how the addition of Silverback Therapeutics to your portfolios can decrease your overall portfolio volatility.